22G-ProCore vs 22G-Standard Needle in Diagnosis of Lymphadenopathy by EBUS-TBNA

Not Applicable

Recruiting

• Conditions: Lymph Node Disease

• Registration Number: NCT03903471
• Lead Sponsor: Jiayuan Sun

Brief Summary

The aim of this study is to compare the performance of 22G-ProCore and 22G-Standard needle in diagnosis of mediastinal and hilar lymphadenopathy via EBUS-TBNA with the purpose to explore the optimal technique for obtaining diagnostic material.

Detailed Description

EBUS-TBNA is an important minimally invasive tool for the diagnosis of mediastinal and hilar lymphadenopathy. The investigators will explore the performance of two kinds of needles and different methods to obtain tissues via EBUS-TBNA in the study. The study is designed as a prospective, single-center, randomized controlled trial, 600 patients will be expected to enroll in the study and randomly assigned to two groups, the 22G-ProCore group and the 22G-Standard group. The primary aim is to compare the diagnostic yields of the two types of needles. The secondary endpoint is to assess the quality of histologic specimen. Meanwhile, stylet slow-pull or negative suction techniques and different agitations (10, 20, 30 times) that each pass includes will be evaluated in the study as well.

Study Timeline

• Study First Submitted: 2019-03-31
• Study First Submitted QC: 2019-04-03
• Study First Posted: 2019-04-04
• Status Verified: 2022-09
• Last Update Submitted: 2022-09-27
• Last Update Posted: 2022-09-29
• Study Start: 2022-10-08
• Primary Completion: 2023-10-08
• Study Completion: 2023-10-08

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

1. Imaging examination indicates enlarged intrathoracic lymph nodes need pathological diagnosis (any lymph node has a short diameter > 1 cm in CT or PET-CT SUV value > 2.5).
2. Accessible mediastinal and hilar lymphadenopathy to EBUS-TBNA.
3. Inform consent signed.

Exclusion Criteria

1. Contraindications of EBUS-TBNA. Such as use of anticoagulant therapy or presence of a coagulopathy (platelet count < 50000 or INR > 1.5).
2. Severe cardiopulmonary dysfunction and other indications that can't tolerate bronchoscopy.
3. Life expectancy less than 6 months.
4. Uncooperative patients.
5. Patients representing vulnerable populations (prisoners, pregnant women, etc).
6. Researchers consider it inappropriate to participate in this study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Diagnostic yield of 22G-ProCore needle	up to 6 months	Diagnostic yield is defined as percentage of specimens in which diagnostic material is obtained.
Diagnostic yield of 22G-Standard needle	up to 6 months	Diagnostic yield is defined as percentage of specimens in which diagnostic material is obtained.

Secondary Outcome Measures

Name	Time	Method
The quality of histologic specimen used by 22G-ProCore needle	up to 6 months	The number and ratio of cellularity, blood contamination, and core-tissue acquisition.
The quality of histologic specimen used by 22G-Standard needle	up to 6 months	The number and ratio of cellularity, blood contamination, and core-tissue acquisition.

Trial Locations

Locations (1)

Shanghai Chest Hospital; 🇨🇳 Shanghai, Shanghai, China